サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1758041

鳥インフルエンザ治療の世界市場

Bird Flu Treatment

出版日
ページ情報
英文 285 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.66円
鳥インフルエンザ治療の世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 285 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

鳥インフルエンザ治療の世界市場は2030年までに346億米ドルに達する見込み

2024年に249億米ドルと推定される鳥インフルエンザ治療の世界市場は、2024～2030年の分析期間においてCAGR 5.6%で成長し、2030年には346億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗ウイルス治療は、CAGR 5.0%を記録し、分析期間終了までに138億米ドルに達すると予測されます。併用治療セグメントの成長率は、分析期間中CAGR 4.7%と推定されます。

米国市場は68億米ドルと推定、中国はCAGR 8.8％で成長予測

米国の鳥インフルエンザ治療市場は、2024年に68億米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 8.8%で推移し、2030年には69億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.8%と5.5%と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界の鳥インフルエンザ治療市場- 主要動向と促進要因のまとめ

なぜ鳥インフルエンザ治療は世界の公衆衛生とバイオ医薬品のイノベーションにとって緊急の焦点なのか？

鳥インフルエンザ（鳥インフルエンザ）は、世界の公衆衛生と養鶏産業の両方にとって、依然として持続的かつ進化する脅威です。H5N1型、H7N9型などのA型インフルエンザ・ウイルスによって引き起こされる鳥インフルエンザは、主に鳥類に感染しますが、感染動物との密接な接触や汚染された環境を通してヒトに感染する能力を持っています。ヒトに感染することは比較的稀であるが、特に高病原性鳥インフルエンザ（HPAI）株の場合、しばしば重篤な呼吸器疾患を引き起こし、高い死亡率を示します。アジア、欧州、アフリカ、南北アメリカで発生が繰り返されており、効果的な鳥インフルエンザ治療と迅速な対応戦略に対する需要はかつてないほど高まっています。鳥インフルエンザウイルスの人獣共通感染症的な性質（動物からヒトへ感染する能力）は、過去のインフルエンザ・パンデミックで証明されているように、重大なパンデミック・リスクをもたらします。さらに、鳥インフルエンザウイルスにおける薬剤耐性株の増加や遺伝子変異の蔓延は、治療努力を複雑にし、新規抗ウイルス薬、治療抗体、支持療法プロトコルの開発の緊急性を強調しています。治療には通常、オセルタミビルやザナミビルのようなノイラミニダーゼ阻害薬が用いられるが、その効果は菌株や投与時期によって異なります。薬理学的介入に加えて、酸素補給、輸液管理、重症例では人工呼吸などの支持療法が重要です。鳥インフルエンザ治療市場は単なるヘルスケア問題ではなく、世界中のバイオセキュリティおよびパンデミック対策戦略の重要な要素です。

科学技術の進歩は鳥インフルエンザ治療薬の状況をどのように変えているのか？

科学技術の革新は、治療法の有効性と展望の両方を拡大することにより、鳥インフルエンザ治療の将来の形を変える上で極めて重要な役割を果たしています。オセルタミビル（タミフル）やザナミビル（リレンザ）といった伝統的な抗ウイルス薬が第一選択薬として使用され続けているが、特定のH5株やH7株における耐性化が進み、新しい薬剤クラスや併用療法の開発が促されています。研究者たちは現在、ポリメラーゼ阻害剤、モノクローナル抗体、ウイルス複製に関与する細胞経路を標的とする宿主指向性療法を模索しています。COVID-19ワクチンの成功に触発されたmRNAベースの治療薬は、カスタマイズされたタンパク質抗原や免疫調整成分を用いて、新興の鳥インフルエンザ株を迅速に標的とするために適応されつつあります。抗ウイルス薬に加えて、回復血漿療法や免疫グロブリン治療が、重症感染時の患者の回復を促進する能力について研究されています。診断の進歩、特にRT-PCRやCRISPRベースのポイント・オブ・ケア・ツールのような分子診断学は、感染の早期発見とタイムリーな治療開始を可能にし、合併症の減少に不可欠な要素です。AIやバイオインフォマティクスは、ウイルスの進化をマップし、変異パターンを予測するために活用されており、将来を見据えて治療法を設計し、世界の備蓄戦略を導くのに役立っています。さらに、世界の保健機関と製薬会社の協力により、鳥インフルエンザ治療薬の臨床試験と承認プロセスが加速しています。このような技術革新は、臨床転帰を向上させるだけでなく、将来の鳥インフルエンザ発生に対してより機敏で効果的な対応ができるよう、ヘルスケアシステムを整えています。

鳥インフルエンザ治療と準備の取り組みをリードしている世界市場と医療システムは？

鳥インフルエンザ治療とアウトブレイク対応を進める取り組みは、家禽の密度が高く、過去にアウトブレイクが発生したことがあり、ヘルスケアのインフラがしっかりしている地域に集中しています。中国、ベトナム、インドネシア、タイを含む東アジアおよび東南アジアの国々は、野鳥と家禽の両方で鳥インフルエンザが頻繁に発生しているため、サーベイランスと治療開発の最前線にいます。特に中国は、H7N9の大規模発生後、鳥インフルエンザの調査、診断、ワクチン製造に多額の投資を行っています。日本と韓国も、早期発見、抗ウイルス剤の備蓄、公衆衛生の調整を組み合わせた統合戦略で注目に値します。北米では、米国とカナダがCDCや米国農務省のような機関の指導の下、迅速な対応、抗ウイルス剤の配布、戦略的な国家備蓄に重点を置いた強固な準備体制を維持しています。米国バイオメディカル先端研究開発局（BARDA）は、官民パートナーシップと連邦政府の資金援助を通じて、鳥インフルエンザ治療の研究開発を支援しています。英国、フランス、ドイツなどの国々が主導する欧州では、人獣共通感染症の脅威を管理するために、ヒト、動物、環境衛生サーベイランスを統合したワンヘルスアプローチを重視しています。一方、WHO、FAO、OIE（現WOAH）などの国際機関は、世界の対応の調整、技術指導、発展途上国における治療アクセスの支援において中心的な役割を果たしています。サハラ砂漠以南のアフリカや南米の一部は、新たな懸念地域であり、限られたヘルスケア・インフラが課題となる一方で、的を絞った介入や能力開発の機会にもなっています。これらすべての地域において、鳥インフルエンザの影響を緩和し、より広範な健康危機への拡大を防ぐためには、治療プロトコルとリアルタイムのアウトブレイク情報および政策枠組みを統合することが不可欠です。

世界の鳥インフルエンザ治療市場の成長を促進しているものは？

世界の鳥インフルエンザ治療市場の成長は、疫学的緊急性、科学的進歩、政策的焦点、パンデミック対策への投資増加の組み合わせによってもたらされています。先進国でも新興諸国でも高病原性鳥インフルエンザが繰り返し発生し、迅速で効果的な治療法の必要性に対する世界の認識が高まっています。鳥インフルエンザ株が変異し、ヒトへのパンデミックを引き起こす可能性があることから、特に鳥インフルエンザ株がヒトからヒトへの持続的な感染能力を獲得した場合、治療法の開発は公衆衛生機関にとっても製薬会社にとっても最優先課題となっています。国家備蓄プログラム、緊急使用許可、抗ウイルス剤研究開発への助成金など、政府の資金援助や戦略的保健イニシアティブも重要な役割を果たしており、市場成長の確固たる基盤となっています。mRNAやモノクローナル抗体プラットフォームが他のウイルス感染症対策に成功したことで、鳥インフルエンザに対する同様の技術への関心と投資が加速しています。さらに、個別化医療や精密医療に対する需要の高まりが、個々の免疫反応やウイルスのサブタイプを考慮した標的治療薬の設計に影響を与えています。世界の旅行や家禽の国際取引の増加、都市化によってウイルス感染のリスクが高まっており、強固な治療インフラの必要性がさらに高まっています。さらに、データ分析、疫学的モデリング、デジタルヘルスツールの進歩は、アウトブレイクの迅速な特定と合理的な治療展開を支援しています。これらの要因を総合すると、鳥インフルエンザ治療市場は拡大するだけでなく、感染症の脅威に対する世界の強靭性を構築することを目的とした、より広範な公衆衛生戦略にも組み込まれつつあります。

セグメント

タイプ（抗ウイルス治療、併用治療、予防的抗生物質治療、リバビリン治療）、エンドユーザー（診療所エンドユーザー、病院エンドユーザー、機関保健センターエンドユーザー、その他エンドユーザー）

調査対象企業の例

  • Abbott
  • BioCryst Pharmaceuticals
  • Boehringer Ingelheim
  • Ceva Sante Animale
  • Cipla
  • CSL Limited（Seqirus）
  • Elanco Animal Health
  • Gilead Sciences
  • GlaxoSmithKline（GSK）
  • Hester Biosciences
  • Macleods Pharmaceuticals
  • Merck & Co.
  • Moderna
  • Novavax
  • Pfizer
  • Phibro Animal Health
  • Roche
  • Sanofi
  • Sinovac Biotech
  • Zoetis

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36390

Global Bird Flu Treatment Market to Reach US$34.6 Billion by 2030

The global market for Bird Flu Treatment estimated at US$24.9 Billion in the year 2024, is expected to reach US$34.6 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Antiviral Treatment, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$13.8 Billion by the end of the analysis period. Growth in the Combination Treatment segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.8 Billion While China is Forecast to Grow at 8.8% CAGR

The Bird Flu Treatment market in the U.S. is estimated at US$6.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.9 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Bird Flu Treatment Market - Key Trends & Drivers Summarized

Why Is Bird Flu Treatment an Urgent Focus for Global Public Health and Biopharmaceutical Innovation?

Bird flu, or avian influenza, remains a persistent and evolving threat to both global public health and the poultry industry. Caused by influenza type A viruses such as H5N1, H7N9, and others, bird flu primarily affects birds but has the capacity to infect humans through close contact with infected animals or contaminated environments. Human infections, though relatively rare, often result in severe respiratory illness and a high mortality rate, especially in the case of highly pathogenic avian influenza (HPAI) strains. With repeated outbreaks occurring in Asia, Europe, Africa, and the Americas, the demand for effective bird flu treatments and rapid response strategies has never been greater. The zoonotic nature of the virus-its ability to jump from animals to humans-poses a significant pandemic risk, as evidenced by past influenza pandemics. Moreover, the increasing prevalence of drug-resistant strains and genetic mutations in avian influenza viruses complicate treatment efforts and underline the urgency of developing novel antiviral drugs, therapeutic antibodies, and supportive care protocols. Treatment typically includes neuraminidase inhibitors like oseltamivir and zanamivir, though their effectiveness varies depending on the strain and timing of administration. In addition to pharmacologic interventions, supportive therapies such as oxygen supplementation, fluid management, and, in severe cases, mechanical ventilation, are crucial. The bird flu treatment market is not just a healthcare issue but a critical component of biosecurity and pandemic preparedness strategies worldwide.

How Are Scientific and Technological Advances Transforming the Landscape of Bird Flu Therapeutics?

Scientific innovation is playing a pivotal role in reshaping the future of bird flu treatment by expanding both the effectiveness and scope of therapeutic options. Traditional antiviral drugs such as oseltamivir (Tamiflu) and zanamivir (Relenza) continue to be used as first-line treatments, but growing resistance among certain H5 and H7 strains has prompted the development of new drug classes and combination therapies. Researchers are now exploring polymerase inhibitors, monoclonal antibodies, and host-directed therapies that target cellular pathways involved in viral replication. mRNA-based therapeutics, inspired by the success of COVID-19 vaccines, are being adapted to rapidly target emerging avian influenza strains with customized protein antigens or immune-modulating components. In addition to antivirals, convalescent plasma therapy and immunoglobulin treatments are being investigated for their ability to boost patient recovery during severe infections. Diagnostic advancements, particularly in molecular diagnostics like RT-PCR and CRISPR-based point-of-care tools, allow for early detection of infection and timely initiation of treatment-an essential factor in reducing complications. AI and bioinformatics are being utilized to map viral evolution and predict mutation patterns, supporting the design of future-proof treatments and guiding global stockpiling strategies. Additionally, collaborations between global health organizations and pharmaceutical companies are accelerating clinical trials and the approval process for bird flu therapeutics. These innovations are not only enhancing clinical outcomes but also preparing healthcare systems for a more agile and effective response to future avian influenza outbreaks.

Which Global Markets and Health Systems Are Leading the Effort in Bird Flu Treatment and Preparedness?

Efforts to advance bird flu treatment and outbreak response are concentrated in regions with high poultry density, previous outbreak history, and strong healthcare infrastructure. Countries in East and Southeast Asia-including China, Vietnam, Indonesia, and Thailand-are at the forefront of surveillance and treatment development due to their frequent exposure to bird flu outbreaks in both wild and domesticated bird populations. China, in particular, has invested heavily in avian influenza research, diagnostics, and vaccine production, especially following large-scale outbreaks of H7N9. Japan and South Korea are also notable for their integrated strategies combining early detection, antiviral stockpiling, and public health coordination. In North America, the United States and Canada maintain robust preparedness frameworks under the guidance of agencies like the CDC and USDA, focusing on rapid response, antiviral distribution, and strategic national stockpiles. The U.S. Biomedical Advanced Research and Development Authority (BARDA) supports bird flu treatment R&D through public-private partnerships and federal funding. Europe, led by countries such as the UK, France, and Germany, emphasizes One Health approaches, integrating human, animal, and environmental health surveillance to manage zoonotic threats. Meanwhile, international organizations like the WHO, FAO, and OIE (now WOAH) play a central role in coordinating global responses, providing technical guidance, and supporting treatment accessibility in developing nations. Sub-Saharan Africa and parts of South America are emerging areas of concern, where limited healthcare infrastructure poses challenges but also presents opportunities for targeted intervention and capacity-building. Across all these regions, the integration of treatment protocols with real-time outbreak intelligence and policy frameworks is essential to mitigating the impacts of bird flu and preventing its escalation into a broader health crisis.

What Is Fueling the Growth in the Global Bird Flu Treatment Market?

The growth in the global bird flu treatment market is driven by a combination of epidemiological urgency, scientific advancement, policy focus, and increased investment in pandemic preparedness. The repeated emergence of highly pathogenic avian influenza outbreaks in both developed and developing countries has heightened global awareness of the need for rapid, effective therapeutic options. The potential for bird flu strains to mutate and cause a human pandemic-especially as they acquire capabilities for sustained human-to-human transmission-has made treatment development a top priority for public health agencies and pharmaceutical companies alike. Government funding and strategic health initiatives are also playing a critical role, with national stockpiling programs, emergency use authorizations, and grants for antiviral R&D providing a solid foundation for market growth. The success of mRNA and monoclonal antibody platforms in combating other viral infections has accelerated interest and investment in similar technologies for avian influenza. Additionally, the growing demand for personalized and precision medicine is influencing the design of targeted therapeutics that account for individual immune responses and viral subtypes. The rise of global travel, international poultry trade, and urbanization are increasing the risk of virus transmission, further driving the need for robust treatment infrastructure. Furthermore, advancements in data analytics, epidemiological modeling, and digital health tools are supporting faster identification of outbreaks and streamlined therapeutic deployment. Collectively, these factors are not only expanding the market for bird flu treatments but are also embedding it into broader public health strategies aimed at building global resilience against infectious disease threats.

SCOPE OF STUDY:

The report analyzes the Bird Flu Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment, Ribavirin Treatment); End-Use (Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott
  • BioCryst Pharmaceuticals
  • Boehringer Ingelheim
  • Ceva Sante Animale
  • Cipla
  • CSL Limited (Seqirus)
  • Elanco Animal Health
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Hester Biosciences
  • Macleods Pharmaceuticals
  • Merck & Co.
  • Moderna
  • Novavax
  • Pfizer
  • Phibro Animal Health
  • Roche
  • Sanofi
  • Sinovac Biotech
  • Zoetis

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Bird Flu Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Frequency of Zoonotic Outbreaks Throws the Spotlight on Antiviral and Supportive Therapies for Bird Flu
    • Global Pandemic Preparedness Initiatives Spur Accelerated R&D in Avian Influenza Therapeutics
    • Here's How Government Stockpiling and Emergency Use Authorizations Are Driving Demand for Antiviral Inventories
    • Mutation and Strain Variability in H5N1 and H5N8 Challenge the Development of Broad-Spectrum Treatments
    • Growing Investment in One Health Strategies Strengthens the Business Case for Cross-Species Influenza Therapies
    • Increased Surveillance and Early Detection Capabilities Propel Rapid Response Infrastructure for Treatment Access
    • Public Health Campaigns and Awareness Drive Uptake of Preventive and Post-Exposure Antiviral Treatments
    • Here's the Story: How Repurposed Drugs Like Oseltamivir and Baloxavir Are Gaining Renewed Focus Amid Resurgent Cases
    • Global Veterinary and Human Health Convergence Creates Demand for Dual-Purpose Treatment Protocols
    • Challenges in Viral Resistance and Therapeutic Efficacy Propel Demand for Next-Generation Influenza Inhibitors
    • Expansion of mRNA and DNA Platform Technologies Fuels Future Opportunities in Rapid Therapeutic Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bird Flu Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bird Flu Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bird Flu Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Bird Flu Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antiviral Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antiviral Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antiviral Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Combination Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Combination Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Combination Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Prophylactic Antibiotics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Prophylactic Antibiotics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Prophylactic Antibiotics Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ribavirin Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ribavirin Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Ribavirin Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Institutional Health Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Institutional Health Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Institutional Health Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Bird Flu Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Bird Flu Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Bird Flu Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Bird Flu Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Bird Flu Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Bird Flu Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Bird Flu Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Bird Flu Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Bird Flu Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Bird Flu Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Bird Flu Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Bird Flu Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION